The standard semaglutide weight loss dosage chart for Wegovy escalates from 0.25 mg weekly to a 2.4 mg weekly maintenance dose over about 16 weeks. The schedule is designed to limit nausea and keep people on therapy long enough to benefit. This article shows the chart, explains why it is structured that way, and underscores that your actual dose is set by a licensed clinician, not by a chart on the internet.
The Standard Wegovy Titration
Wegovy is the FDA-approved brand of semaglutide for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, as well as for adolescents 12 and older who meet weight criteria. The titration below reflects the FDA label.
| Week | Weekly Dose | Purpose |
|---|---|---|
| 1-4 | 0.25 mg | Starting dose to introduce the drug |
| 5-8 | 0.5 mg | First escalation |
| 9-12 | 1.0 mg | Second escalation |
| 13-16 | 1.7 mg | Third escalation |
| 17+ | 2.4 mg | Maintenance dose for chronic weight management |
If side effects are intense at any step, the clinician may hold the patient at the current dose for another 4 weeks before moving up. A small percentage of people never reach the full 2.4 mg and settle at 1.7 mg long term.
Wegovy vs Ozempic Dosing
Wegovy and Ozempic both contain semaglutide, but they are approved for different conditions and top out at different doses. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management.
| Feature | Wegovy (weight loss) | Ozempic (type 2 diabetes) |
|---|---|---|
| Starting dose | 0.25 mg weekly | 0.25 mg weekly |
| Typical maintenance | 2.4 mg weekly | 1.0 to 2.0 mg weekly |
| Titration length | ~16 weeks | ~8 to 20 weeks |
| Primary indication | Chronic weight management | Type 2 diabetes glucose control |
| Secondary approvals | Cardiovascular risk reduction (eligible patients), adolescents 12+ | Cardiovascular risk reduction in adults with type 2 diabetes |
Why the Slow Ramp Matters
Semaglutide slows stomach emptying and blunts appetite signals. Those actions are central to its benefit and to its side-effect profile. Starting at 2.4 mg would cause severe nausea, vomiting, and dehydration in most people and drive high drop-out rates. The four-week steps let the gut adapt between dose increases.
Compliance drives results. In trials, participants who reached and maintained 2.4 mg for the full 68 weeks lost the most weight. People who stopped early or stayed at lower doses saw proportionally smaller losses.
Expected Weight Loss at Each Dose
Most of the weight-loss benefit accumulates after reaching the maintenance dose, not during titration. Trial data from STEP-1 show average trajectories, but individuals vary widely.
- Weeks 1 to 16 (titration): 2 to 5 percent of body weight lost on average, driven mostly by reduced appetite.
- Weeks 16 to 40 (early maintenance): Weight loss accelerates as 2.4 mg takes full effect.
- Weeks 40 to 68: Loss slows and stabilizes; average total loss at week 68 was about 14.9 percent on drug vs 2.4 percent on placebo.
- Beyond week 68: Maintenance requires continued medication plus lifestyle; discontinuation typically leads to significant regain.
Side Effects During Titration
Expect GI symptoms, especially in the first week of a new dose. Nausea, diarrhea, constipation, vomiting, reflux, and fatigue are the most common. Severe or persistent symptoms warrant a call to the prescribing clinician. Less common but serious events include pancreatitis, gallbladder disease, kidney injury from dehydration, and allergic reactions. Semaglutide also carries a boxed warning about thyroid C-cell tumors seen in rodent studies; it is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
When Someone Might Stay Below 2.4 mg
Some people tolerate lower doses better and maintain adequate weight loss at 1.7 mg or even 1.0 mg. Reasons to stop titrating include persistent nausea or vomiting, significant reflux, early satiety so intense that protein intake drops, or lab changes that concern the clinician. Staying below 2.4 mg is not failure; it is individualized care.
Who Should Avoid Semaglutide
People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use semaglutide. Other reasons to avoid include active pancreatitis, severe gastroparesis, known serious allergy to the drug, and pregnancy. Caution is also needed with kidney disease, gallbladder disease, and use alongside insulin or sulfonylureas due to hypoglycemia risk. For broader context, see our guide to A1C levels and our treatment hub.
Lifestyle Still Drives Long-Term Outcomes
Wegovy trial participants received structured counseling on food, activity, and behavior. Real-world outcomes often fall short of trial averages when that scaffolding is missing. Aim for adequate protein (roughly 1.2 to 1.6 g per kilogram body weight daily), resistance training two to three times a week, and seven to nine hours of sleep. For food framework ideas, explore our diet and nutrition hub.
The Bottom Line
The semaglutide weight loss dosage chart is a roadmap, not a prescription. Reaching 2.4 mg weekly tends to produce the largest average weight loss, but the right dose for you is the one your clinician lands on based on response and tolerability. Review official prescribing details on the FDA drug safety site and bring specific questions to your next appointment.
Medical disclaimer: This article is for educational purposes only. It does not replace diagnosis, dosing guidance, or treatment decisions made by your clinician. Do not start, stop, or adjust any medication without professional medical advice.
